Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4) is a pentameric ligand-gated ion channel formed by the assembly of α3 and β4 subunits, predominantly expressed in autonomic ganglia and select brain regions involved in reward circuitry and addiction. Upon binding endogenous acetylcholine or exogenous agonists like nicotine, the channel opens to conduct sodium and potassium ions, mediating fast synaptic transmission and modulating both peripheral and central nervous system signaling. The α3β4 nAChR is a validated therapeutic target for addiction, notably nicotine dependence, and is also implicated in neurodegenerative and cardiovascular diseases; numerous agonists, antagonists, and modulators, including selective small molecules such as AT-1001, are under investigation for clinical and research applications. The receptor's structure displays a pentameric arrangement, with high-resolution images revealing ligand binding domains that confer pharmacological selectivity; its physiological, therapeutic, and side effect profile remains a focal point for CNS and autonomic drug development.
Agonists induce channel opening to allow cation influx (Na+, K+), depolarizing post- or presynaptic neurons Antagonists block ion channel function, inhibiting neurotransmission Partial agonists modulate channel with lower efficacy Noncompetitive antagonists block function via allosteric or channel pore binding
16 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4).